We fight for human health.

CureVac is the first company to successfully harness messenger RNA (mRNA) for medical purposes. The principle is promising: use natural mRNA as a data carrier to instruct the human body to produce its own proteins to fight a wide range of diseases.

  • CureVac Highlights Key 2018 Corporate Milestones and Outlook at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco

    Press Release of January 10, 2018 / View webcast of CureVac’s presentation

    Read more
  • CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    Press Release of January 4, 2018

    Read more
  • CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

    Press Release of November 13, 2017

    Read more
  • Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    Press Release of October 18, 2017

    Read more
  • "A successful founder off the beaten path"

    CureVac's history published in Nature Biotechnology on Oct 11, 2017

    Read more
  • Work@CureVac

    Do you want to fight together with us for human health? You will find current vacancies on our CareerPortal.

    Read more